IPOX® CEO Josef Schuster commented in a recent Reuters article, "Karman Holdings valued at nearly $4 billion as shares jump in NYSE debut", offering expert analysis on Karman Holdings' successful IPO and the broader market trends favoring defense and space companies.

IPOX® CEO Josef Schuster was quoted in a recent Reuters article, "Cybersecurity firm SailPoint sets sights on $12.6 billion valuation in US IPO", providing expert insight into SailPoint's IPO and the broader implications for the technology IPO market.

IPOX® Research Analyst Lukas Muehlbauer offered his perspective on the market debut of Maze Therapeutics (MAZE.O), a drug developer focused on chronic kidney diseases. Maze's shares saw a modest 1% increase on its Nasdaq debut, valuing the company at $690.37 million. The company’s debut follows an upsized IPO that raised $140 million.

IPOX® Research Analyst Lukas Muehlbauer offered his expert perspective on the market debut of Metsera, a GLP-1 weight-loss drug developer that achieved a $2.7 billion valuation following a 42% surge in its Nasdaq IPO. Metsera's strong performance underscores the robust investor appetite within the innovative obesity therapeutics sector.

IPOX® CEO Josef Schuster told Reuters that Venture Global's IPO "low float" presents a "significant risk," underscoring a challenging environment for energy IPOs to achieve high premiums and highlighting the importance of float considerations in new listings.

IPOX® CEO Josef Schuster told Bloomberg that Venture Global's IPO valuation cut "jolts" the market, signaling a crucial shift: investors now demand realistic valuations and rigorous IPO deal scrutiny, emphasizing increased investor discipline as the new norm.

IPOX® Research Analyst Dr. Lukas Muehlbauer, offered his perspective on the upcoming US IPO of Ascentage Pharma, a Chinese biopharmaceutical firm targeting a valuation of $1.75 billion. Ascentage, backed by Takeda Pharmaceutical, is seeking a US listing after its shares have already been trading on the Hong Kong stock exchange since 2019.

IPOX® CEO Josef Schuster shared his insights on the upcoming IPO of Smithfield Foods, which aims for a valuation of up to $10.73 billion. The pork producer's return to the U.S. stock market after over a decade is one of the first major consumer IPOs of the year, potentially setting a precedent for other companies in the sector.

IPOX® CEO Josef Schuster spoke with Bloomberg about the expected rebound in US energy IPOs, driven by companies like Venture Global. Schuster noted rising commodity prices and recent IPO successes create a favorable environment, adding that the market is "ready for a slew of good energy IPOs."

IPOX® CEO Josef Schuster sat down with Chuck Jaffe on the Money Life with Chuck Jaffe podcast to discuss the state of the IPO market, its strong performance amid market highs, and the factors driving its momentum. Schuster highlighted the role of low interest rates, robust earnings, and the rise of sectors like AI and industrials in fueling IPO growth.

Josef Schuster, founder and CEO of IPOX Schuster LLC, was recently featured in Reuters, offering his perspective on the upcoming IPO of ServiceTitan, which aims for a valuation of up to $5.16 billion.

IPOX® CEO Josef Schuster shared insights with Bloomberg on the renewed optimism in Canada’s IPO market, highlighted by Groupe Dynamite Inc.’s C$300 million debut. Schuster emphasized the IPOX® Canada Opportunities Index's adaptability, which has delivered a strong 36% return this year, outperforming the S&P/TSX Composite Index. The index reflects growing investor confidence and emerging opportunities as Canada’s equity markets show signs of recovery.

IPOX® CEO Josef Schuster, portfolio manager and subadvisor to the Rakuten Global IPO Stock Fund, was featured in Japan’s Nikkei Newspaper (日本経済新聞), talking about Reddit’s impressive post-IPO growth, underscoring IPOX's focus on identifying high-potential companies in the evolving global IPO landscape.

IPOX® Research Analyst Dr. Lukas Muehlbauer commented on Septerna's upsized U.S. IPO as the Goldman Sachs-backed drug developer targets a valuation of $743.1 million. Septerna, originally planning to offer 10.9 million shares within a $15-$17 range, has now increased its offering to 15.3 million shares, pricing them at $18 each, to raise approximately $275 million. This move reflects positive investor sentiment for biotech IPOs, which have seen strong performances in the U.S. market this fall.

In a recent Reuters article, IPOX® CEO Dr. Josef Schuster highlighted the strategic timing behind Ingram Micro's return to the U.S. stock market, as the global technology distributor seeks a valuation of up to $5.42 billion. Schuster emphasized that private equity firms, like Ingram's backer Platinum Equity, are capitalizing on favorable market conditions, strong demand, and the opportunity to monetize their investments.

In a recent Reuters article, IPOX® Research Analyst Dr. Lukas Muehlbauer discussed the strong debut of Upstream Bio (UPB.O) in the IPO market. The Waltham, Massachusetts-based drug developer saw its stock rise 26.5% above the IPO price, giving it a market value of $1.05 billion.

In a recent Reuters article, IPOX® research analyst Lukas Muehlbauer highlighted strong institutional and retail demand for Bicara Therapeutics' IPO, which raised $315 million after upsizing twice. Bicara’s shares surged 46% in its debut, driven by confidence in its lead anti-cancer drug and notable backing from TPG and Biocon.

In Bloomberg, IPOX® CEO Josef Schuster discussed the resurgence of SPACs, noting $2 billion raised in August. He emphasized SPACs as a viable alternative to traditional IPOs for niche sectors, with renewed interest from sponsors. IPOX® tracks these trends as companies explore new public listing avenues.

Seeking Alpha published an analysis of the First Trust US Equity Opportunities ETF (FPX), which tracks our IPOX® 100 U.S. Index. The article states that "FPX is larger, more liquid, and better diversified" than its closest competitor.

In a CNN Arabic interview, IPOX® Schuster CEO Josef Schuster discussed China's reduction in U.S. debt holdings, highlighting its shift to gold and raw materials. He emphasized the need for the U.S. to manage its $34 trillion debt and rising servicing costs while expressing optimism about increased domestic investment in U.S. Treasuries.